The ubiquitin-proteasome system in HIV replication: potential targets for antiretroviral therapy (Q36066214)

12 August 2017

1 reference

title

The ubiquitin-proteasome system in HIV replication: potential targets for antiretroviral therapy (English)

1 reference

ubiquitin-proteasome system

12 August 2017

0 references

anti-retroviral agent

0 references

author name string

Patricia P Klinger

series ordinal

1

1 reference

PubMed ID

15757458

12 August 2017

Ulrich Schubert

series ordinal

2

1 reference

12 August 2017

1 February 2005

1 reference

Expert Review of Anti-infective Therapy

12 August 2017

1 reference

12 August 2017

3

1 reference

12 August 2017

61-79

1 reference

12 August 2017

1

1 reference

The brightening future of HIV therapeutics

12 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

Adverse effects of antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

Perspectives series: host/pathogen interactions. Dynamics of HIV-1 replication in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

Classifying reverse transcribing elements: a proposal and a challenge to the ICTV. International Committee on Taxonomy of Viruses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

HIV receptors and cellular tropism

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

Identification of a major co-receptor for primary isolates of HIV-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

Charting HIV's remarkable voyage through the cell: Basic science as a passport to future therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

Slipping through the door: HIV entry into the nucleus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

Mechanisms of enveloped RNA virus budding

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

Atomic structure of the ectodomain from HIV-1 gp41

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

Effect of mutations affecting the p6 gag protein on human immunodeficiency virus particle release

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

HIV-1 gag proteins: diverse functions in the virus life cycle

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

A novel gene of HIV-1, vpu, and its 16-kilodalton product

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

HIV-1 and Ebola virus: the getaway driver nabbed

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

Resistance is futile: assimilation of cellular machinery by HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

Ubiquitin in retrovirus assembly: actor or bystander?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

Potential roles of cellular proteins in HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

Cyclophilin A retrotransposition into TRIM5 explains owl monkey resistance to HIV-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

Structural characterization of the HIV-1 Vpr N terminus: evidence of cis/trans-proline isomerism

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

Cyclophilin A interacts with HIV-1 Vpr and is required for its functional expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

Human immunodeficiency virus type 1 Vpr-mediated G(2) cell cycle arrest: Vpr interferes with cell cycle signaling cascades by interacting with the B subunit of serine/threonine protein phosphatase 2A

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

TFIIH inhibits CDK9 phosphorylation during human immunodeficiency virus type 1 transcription

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

Effects of pharmacological cyclin-dependent kinase inhibitors on viral transcription and replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

Cyclin-dependent kinases as cellular targets for antiviral drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

Role of ESCRT-I in retroviral budding

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

The Protein Network of HIV Budding

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

Tsg101 and the vacuolar protein sorting pathway are essential for HIV-1 budding

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

HIV-1 and Ebola virus encode small peptide motifs that recruit Tsg101 to sites of particle assembly to facilitate egress

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

Tsg101, an inactive homologue of ubiquitin ligase e2, interacts specifically with human immunodeficiency virus type 2 gag polyprotein and results in increased levels of ubiquitinated gag.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

Tsg101, a homologue of ubiquitin-conjugating (E2) enzymes, binds the L domain in HIV type 1 Pr55(Gag)

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

The late domain of human immunodeficiency virus type 1 p6 promotes virus release in a cell type-dependent manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

Structure and functional interactions of the Tsg101 UEV domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

AIP1/ALIX Is a Binding Partner for HIV-1 p6 and EIAV p9 Functioning in Virus Budding

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

Hrs regulates multivesicular body formation via ESCRT recruitment to endosomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

Mammalian tumor susceptibility gene 101 (TSG101) and the yeast homologue, Vps23p, both function in late endosomal trafficking.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

Receptor downregulation and multivesicular-body sorting

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

Non-traditional functions of ubiquitin and ubiquitin-binding proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

Recent insights into HIV-1 Vif.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

Transcriptional regulation of APOBEC3G, a cytidine deaminase that hypermutates human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

21 January 2018

Death and the retrovirus

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

DNA deamination mediates innate immunity to retroviral infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

Phosphorylation of a novel SOCS-box regulates assembly of the HIV-1 Vif-Cul5 complex that promotes APOBEC3G degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

HIV-1 Vif Blocks the Antiviral Activity of APOBEC3G by Impairing Both Its Translation and Intracellular Stability

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

Selective assembly of HIV-1 Vif-Cul5-ElonginB-ElonginC E3 ubiquitin ligase complex through a novel SOCS box and upstream cysteines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

Induction of APOBEC3G Ubiquitination and Degradation by an HIV-1 Vif-Cul5-SCF Complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

Mutual functional destruction of HIV-1 Vpu and host TASK-1 channel

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

HIV-1 Nef mimics an integrin receptor signal that recruits the polycomb group protein Eed to the plasma membrane

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

Inhibition of HIV-1 virion production by a transdominant mutant of integrase interactor 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

HIV-1 cDNA integration: requirement of HMG I(Y) protein for function of preintegration complexes in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

Proteasome inhibition interferes with gag polyprotein processing, release, and maturation of HIV-1 and HIV-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

A soluble ATP-dependent proteolytic system responsible for the degradation of abnormal proteins in reticulocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

The ubiquitin-proteasome pathway: on protein death and cell life

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

Cells adapted to the proteasome inhibitor 4-hydroxy- 5-iodo-3-nitrophenylacetyl-Leu-Leu-leucinal-vinyl sulfone require enzymatically active proteasomes for continued survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

Mechanisms underlying ubiquitination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

Gettin' down with ubiquitin: turning off cell-surface receptors, transporters and channels

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

Antigen processing by the proteasome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

The 26S proteasome: a molecular machine designed for controlled proteolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

Crystal structure of the 20S proteasome from the archaeon T. acidophilum at 3.4 A resolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

Inactivation of a defined active site in the mouse 20S proteasome complex enhances major histocompatibility complex class I antigen presentation of a murine cytomegalovirus protein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

Structure and functions of the 20S and 26S proteasomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

The ubiquitin-proteasome pathway and pathogenesis of human diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

Potential for proteasome inhibition in the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

Preclinical and clinical evaluation of proteasome inhibitor PS-341 for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

Proteasome inhibitors as new anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

The development of proteasome inhibitors as anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

The proteasome: structure, function, and role in the cell

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

Development of the proteasome inhibitor Velcade (Bortezomib).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

The ubiquitin-mediated protein degradation pathway in cancer: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

The proteasome, a new target for cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

Inhibitors of the eukaryotic 20S proteasome core particle: a structural approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

Proteasome inhibitors: valuable new tools for cell biologists

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

Proteasome inhibitors: from research tools to drug candidates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

The ubiquitin-proteasome pathway and proteasome inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

Proteasomes as Drug Targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

A phase 2 study of bortezomib in relapsed, refractory myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

Retroviruses have differing requirements for proteasome function in the budding process

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

Ubiquitin-proteasome system and proteasome inhibition: new strategies in stroke therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

Targeting the ubiquitin-proteasome pathway in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

Cancer research. Taking garbage in, tossing cancer out?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

Ubiquitin and breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

Bortezomib and its role in the management of patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

Bortezomib as a potential treatment for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

The role of proteasome inhibitors in solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

A review of the proteasome inhibitor bortezomib in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

Proteasome inhibition in hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

Not just research tools--proteasome inhibitors offer therapeutic promise

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

A beta-lactone related to lactacystin induces neurite outgrowth in a neuroblastoma cell line and inhibits cell cycle progression in an osteosarcoma cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

Separation of cathepsin A-like enzyme and the proteasome: evidence that lactacystin/beta-lactone is not a specific inhibitor of the proteasome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

Effect of the proteasome inhibitor MLN519 on the expression of inflammatory molecules following middle cerebral artery occlusion and reperfusion in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

The proteasome: a new target for novel drug therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

Delayed treatment of ischemia/reperfusion brain injury: extended therapeutic window with the proteosome inhibitor MLN519.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

Postischemic (6-Hour) treatment with recombinant human tissue plasminogen activator and proteasome inhibitor PS-519 reduces infarction in a rat model of embolic focal cerebral ischemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

Total synthesis of the potent proteasome inhibitor epoxomicin: a useful tool for understanding proteasome biology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

Bivalency as a principle for proteasome inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

Global analysis of proteasomal substrate specificity using positional-scanning libraries of covalent inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

Ubiquitin in avian leukosis virus particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

Ubiquitination of HIV-1 and MuLV Gag.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

Equine infectious anemia virus and the ubiquitin-proteasome system

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

A role for ubiquitin ligase recruitment in retrovirus release

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

Membrane transport: ubiquitylation in endosomal sorting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

Ubiquitin is part of the retrovirus budding machinery

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

The late-domain-containing protein p6 is the predominant phosphoprotein of human immunodeficiency virus type 1 particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

Transient aggregation of ubiquitinated proteins during dendritic cell maturation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

Quantitating protein synthesis, degradation, and endogenous antigen processing

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

Budding of equine infectious anemia virus is insensitive to proteasome inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

The tails of ubiquitin precursors are ribosomal proteins whose fusion to ubiquitin facilitates ribosome biogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

Late domain-dependent inhibition of equine infectious anemia virus budding

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

HIV's response to a CCR5 inhibitor: I'd rather tighten than switch!

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

A single amino acid substitution in the ICP27 protein of herpes simplex virus type 1 is responsible for its resistance to leptomycin B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

The poliovirus replication machinery can escape inhibition by an antiviral drug that targets a host cell protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

Host cell gene expression during human immunodeficiency virus type 1 latency and reactivation and effects of targeting genes that are differentially expressed in viral latency

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

Ubiquitin-protein ligases--novel therapeutic targets?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

Tal, a Tsg101-specific E3 ubiquitin ligase, regulates receptor endocytosis and retrovirus budding

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

A new rac target POSH is an SH3-containing scaffold protein involved in the JNK and NF-kappaB signalling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

POSH acts as a scaffold for a multiprotein complex that mediates JNK activation in apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

The trans-Golgi network-associated human ubiquitin-protein ligase POSH is essential for HIV type 1 production

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

Covalent modification of human immunodeficiency virus type 1 p6 by SUMO-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

HECT ubiquitin ligases link viral and cellular PPXY motifs to the vacuolar protein-sorting pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

A PPxY motif within the VP40 protein of Ebola virus interacts physically and functionally with a ubiquitin ligase: implications for filovirus budding

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

Late assembly motifs of human T-cell leukemia virus type 1 and their relative roles in particle release

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

Functional involvement of a novel Nedd4-like ubiquitin ligase on retrovirus budding

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

Absconding with the Chaperone: Essential Cyclophilin–Gag Interaction in HIV-1 Virions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

WW domains and retrovirus budding

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

A proteolytic system that compensates for loss of proteasome function

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

The major substrates for TAP in vivo are derived from newly synthesized proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

Perfect use of imperfection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.1.61

Eponemycin, a new antibiotic active against B16 melanoma. I. Production, isolation, structure and biological activity

21 January 2018

1 reference

12 April 2024

https://opencitations.net/index/api/v1/citations/10.7164/ANTIBIOTICS.43.8

Identifiers

DOI

10.1586/14787210.3.1.61

1 reference

12 August 2017

1 reference

PubMed ID

15757458